Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-07 7:04 pm Purchase |
2025-03-31 | 13G | Celcuity Inc. CELC |
Baker Bros. Advisors LP | 4,257,735 11.300% |
1,579,182 (+58.96%) |
Filing History |
| 2025-03-31 7:35 pm Purchase |
2025-03-27 | 13D | DBV Technologies S.A. DBVT |
Baker Bros. Advisors LP | 23,489,663 17.100% |
23,489,663 (New Position) |
Filing History |
| 2025-03-07 5:07 pm Unchanged |
2025-03-07 | 13D | Replimune Group, Inc. REPL |
Baker Bros. Advisors LP | 11,045,336 14.300% |
0 (Unchanged) |
Filing History |
| 2025-02-14 4:33 pm Purchase |
2025-02-12 | 13D | Sera Prognostics, Inc. SERA |
Baker Bros. Advisors LP | 5,498,170 16.100% |
63,771 (+1.17%) |
Filing History |
| 2025-02-14 4:16 pm Purchase |
2024-12-31 | 13G | Immatics N.V. IMTX |
Baker Bros. Advisors LP | 7,275,830 6.000% |
1,436,977 (+24.61%) |
Filing History |
| 2025-02-14 4:15 pm Purchase |
2024-12-31 | 13G | Celcuity Inc. CELC |
Baker Bros. Advisors LP | 2,678,553 7.200% |
803,575 (+42.86%) |
Filing History |
| 2025-02-14 4:14 pm Purchase |
2024-12-31 | 13G | Candel Therapeutics, Inc. CADL |
Baker Bros. Advisors LP | 2,981,983 6.800% |
2,981,983 (New Position) |
Filing History |
| 2025-02-14 4:12 pm Sale |
2024-12-31 | 13G | Biomea Fusion, Inc. BMEA |
Baker Bros. Advisors LP | 1,451,990 4.000% |
-656,959 (-31.15%) |
Filing History |
| 2024-12-31 4:18 pm Purchase |
2024-12-29 | 13D | Kala Pharmaceuticals, Inc. KALA |
Baker Bros. Advisors LP | 1,201,894 19.700% |
310,559 (+34.84%) |
Filing History |
| 2024-12-17 6:46 pm Purchase |
2024-12-13 | 13D | Bicycle Therapeutics plc BCYC |
Baker Bros. Advisors LP | 10,885,357 22.900% |
1,485,397 (+15.80%) |
Filing History |
| 2024-12-10 9:30 pm Sale |
2024-12-09 | 13D | BeiGene, Ltd. ONC |
Baker Bros. Advisors LP | 125,276,610 13.000% |
-13,401,427 (-9.66%) |
Filing History |
| 2024-11-14 4:27 pm Purchase |
2024-09-30 | 13G | Sagimet Biosciences Inc. SGMT |
Baker Bros. Advisors LP | 1,538,489 4.990% |
81,971 (+5.63%) |
Filing History |
| 2024-11-14 4:26 pm Purchase |
2024-09-30 | 13G | Celcuity Inc. CELC |
Baker Bros. Advisors LP | 1,874,978 5.100% |
1,874,978 (New Position) |
Filing History |
| 2024-11-14 4:24 pm Purchase |
2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK |
Baker Bros. Advisors LP | 4,368,443 8.300% |
4,368,443 (New Position) |
Filing History |
| 2024-11-14 4:23 pm Sale |
2024-09-30 | 13G | Achilles Therapeutics plc ACHL |
Baker Bros. Advisors LP | 0 0.000% |
-3,311,567 (Position Closed) |
Filing History |
| 2024-11-14 4:21 pm Purchase |
2024-09-30 | 13G | Nurix Therapeutics, Inc. NRIX |
Baker Bros. Advisors LP | 6,751,565 9.700% |
1,799,113 (+36.33%) |
Filing History |
| 2024-11-14 4:21 pm Sale |
2024-09-30 | 13G | Aerovate Therapeutics, Inc. AVTE |
Baker Bros. Advisors LP | 628,939 2.200% |
-1,051,578 (-62.57%) |
Filing History |
| 2024-11-14 4:20 pm Purchase |
2024-09-30 | 13G | Replimune Group, Inc. REPL |
Baker Bros. Advisors LP | 11,045,336 16.200% |
1,500,000 (+15.71%) |
Filing History |
| 2024-11-14 4:17 pm Sale |
2024-09-30 | 13G | Athira Pharma, Inc. ATHA |
Baker Bros. Advisors LP | 0 0.000% |
-3,153,807 (Position Closed) |
Filing History |
| 2024-11-14 4:14 pm Purchase |
2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX |
Baker Bros. Advisors LP | 5,840,059 6.200% |
5,840,059 (New Position) |
Filing History |